Migraine
Conditions
Brief summary
This study will evaluate the comparative bioavailability of three capsule formulations of MK-0974.
Interventions
\[INTERVENTION NAME: MK-0974 12MoRT\] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods
DRUGMK-0974 5Mo5C
Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 °C) 300 mg in one of three treatment periods
DRUGMK-0974 12Mo5C
Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 °C) 300 mg in one of three treatment periods
Sponsors
Merck Sharp & Dohme LLC
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
Yes
Inclusion criteria
* Subject is in good health * Subject is a nonsmoker * Subject is willing to comply with the study restrictions
Exclusion criteria
* Subject has a history of stroke, chronic seizures, or major neurological disorder * Subject has a history of cancer * Subject is a nursing mother * Subject has or has a history of any illness that might make participation in the study unsafe or confound the results of the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Area under the curve (AUC(0 to infinity) following single dose administration of MK-0974 12Mo5C and 5Mo5C formulations | Through 48 hours postdose |
| Peak plasma concentration (Cmax) following single dose administration of MK-0974 12Mo5C and 5Mo5C formulations | Through 48 hours postdose |
Secondary
| Measure | Time frame |
|---|---|
| Area under the curve (AUC(0 to infinity) following single dose administration of MK-0974 12MoRT and 5Mo5C formulations | Through 48 hours postdose |
| Peak plasma concentration (Cmax) following single dose administration of MK-0974 12MoRT and 5Mo5C formulations | Through 48 hours postdose |
Outcome results
None listed